Skip to main content
SpringerLink
Log in

Aberrant responses of human lymphocytic neoplasms to cytokine regulation

  • Foreword
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Studies in this laboratory have recently focused on two hemic neoplasms: B cell chronic lymphocytic leukemia (B-CLL) and a T cell disorder, Sézary syndrome. These tumors do not have consistent cytogenetic or molecular genetic alterations, and so we have concentrated on their response to and production of various regulatory cytokines. Although B-CLL cells show variable proliferative responses when exposed to transforming growth factor beta (TGFΒ), these cells have consistently shown resistance to the proapoptotic effects of this cytokine. Also, interleukin 4 (IL4), IL5, and interferon-gamma (IFNγ) all show a consistently increased protective effect against apoptosis in B-CLL cells as compared to normal human B cells. Thus, a defect in apoptosis appears to be an important factor in the pathogenesis of CLL. By contrast, the neoplastic T cells of Sézary syndrome show a consistent resistance to the antiproliferative effects of TGFΒ, suggesting that aberrant proliferation is more important than apoptosis in this disorder. In both neoplasms, we have shown that the defective responses to cytokines are in some instances related to alterations in receptor expression, but this has not been true in all circumstances, and other stages in the signaling pathways are being investigated. As we define more precisely the specific defects that contribute to the clonal expansion of these neoplasms, the findings may ultimately lead to improved clinical control of these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nowell PC: Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Cancer Genet Cytogenet 1997;94:13–20.

    Article  PubMed  CAS  Google Scholar 

  2. Moore JS, Friedman DF, Silberstein LE, Besa EC, Nowell PC: Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1995;20:141–164.

    Article  PubMed  CAS  Google Scholar 

  3. Marks DI, Vonderheid EC, Kurz BW, Bigler RD, Sinha K, Morgan DA, et al.: Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome. Br J Haematol 1996;92:890–899.

    Article  PubMed  CAS  Google Scholar 

  4. Thangavelu M, Finn WG, Yelavarthi KK, Roenigk HH, Samuelson E, Peterson LA, et al.: Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood 1997;89:3371–3377.

    PubMed  CAS  Google Scholar 

  5. Kerhl JH, Roberts AB, Wakefield LM, Jakowlew SB, Sporn MB, Fauci AS:Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137:3855–3859.

    Google Scholar 

  6. Wahl SM, Hunt DA, Wong HL, Doughert S, McCartney-Francis N, Wahl LM, et al.: Transforming growth factor beta is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation. J Immunol 1988;140:3026–3030.

    PubMed  CAS  Google Scholar 

  7. Chaouchi N, Arvanitakis L, Auffredou MT, Blanchard DA, Vazquez A, Sharma S: Characterization of transforming growth factor-beta-1 induced apoptosis in normal human B-cells and lymphoma B-cell lines. Oncogene 1995;11:1615–1620.

    PubMed  CAS  Google Scholar 

  8. Trentin L, Cerutti A, Zambello R, Sancetta R, Tassinari C, Facco M, et al.: Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996;87: 3327–3335.

    PubMed  CAS  Google Scholar 

  9. Osario LM, De Santiago A, Aguilar-Santalises M, Mellstedt H, Jondal M: CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B-cells from apoptosis induced by anti-IgM. Blood 1997;89:2833–2841.

    Google Scholar 

  10. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf SF, Singh A, Trinchieri G, Lessin SR:IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491–1498.

    PubMed  CAS  Google Scholar 

  11. McCusker ME, Garifallou M, Bogen SA: Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. J Immunol 1997;158:4984–4991.

    PubMed  CAS  Google Scholar 

  12. Mauer AM: Clinical features of human leukemia; in Mauer AM (ed): The Biology of Human Leukemia. Baltimore, Johns Hopkins University Press, 1990, pp 1–27.

    Google Scholar 

  13. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS: Chronic lymphocytic leukemia B-cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood;1997:89:941–947.

    PubMed  CAS  Google Scholar 

  14. Kremer JP, Reisbach G, Nerl C, Dormer P: B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor -beta. Br J Haematol 1992;80: 480–489.

    PubMed  CAS  Google Scholar 

  15. Lotz M, Raanhein E, Kipps T:Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B-cells. J Exp Med 1994;179:999–1008.

    Article  PubMed  CAS  Google Scholar 

  16. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, et al.:Loss of functional cell surface transforming growth factor beta (TGF-Β) type l receptor correlates with insensitivity to TGFΒ in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94:5877–5881.

    Article  PubMed  CAS  Google Scholar 

  17. Phillips JA, Mehta K, Fernandez C, Raveche ES: The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 1992; 52:437–443.

    PubMed  CAS  Google Scholar 

  18. Phillips J, Raveche E: Immunoregulatory capability of murine CLL-like CD5+ B-cells. Ann NY Acad Sci 1992;651:488–490.

    Article  PubMed  CAS  Google Scholar 

  19. Raveche ES, Lalor P, Stall A, Conroy J: In vivo effects of hyperdiploid Ly-1+ B-cells of NZB origin. J Immunol 1988:141:4133–4139.

    PubMed  CAS  Google Scholar 

  20. Douglas RS, Woo EY, Capocasale RJ, Tarshis AD, Nowell PC, Moore SJ: Altered response to and production of TGF-\ by B-cells from autoimmune NZB mice. Cell Immunol 1997;179:126–131.

    Article  PubMed  CAS  Google Scholar 

  21. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin-4 protects chronic lymphocytic leukemia from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319–1329.

    Article  PubMed  CAS  Google Scholar 

  22. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV:IL-4 inhibits apoptotic cell death and loss of the Bcl-2 protein in B-CLL cells in vitro. Br J Haematol 1993; 85:439–451.

    Article  PubMed  CAS  Google Scholar 

  23. Moore JS, Zaki M, Douglas R, Nowell P: Altered cytokine production by T cells from patients with B-CLL (Abstract). Cytometry 1997, in press.

  24. Buschle M, Campana D, Carding S, Richard C, Hoffbrand AV, Brenner MK: Interferon-gamma inhibits apoptotic cell death in B-cell chronic lymphocytic leukemia. J Exp Med 1993;177:213–218.

    Article  PubMed  CAS  Google Scholar 

  25. Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ: Autoantigen inhibits apoptosis of a human B-cell leukemia that produces pathogenic rheumatoid factor. J Immunol 1993;151:7273–7283.

    PubMed  CAS  Google Scholar 

  26. Rabbitts T: Translocations, master genes and differences between the origins of acute and chronic leukemias. Cell 1991;67:641–653.

    Article  PubMed  CAS  Google Scholar 

  27. Kitada S, Bullrich F, Krajewski S, Zapata J, Andersen J, Hines J, et al.: Bcl-2 family genes, CPP32 protease, 13ql4 deletions, and in vitro sensitivity to fludarabine and 2-chlorodeoxyadenosine in B-CLL: an ECOG study [Abstract]. Proc Am Assoc Cancer Res 1997;38:169.

    Google Scholar 

  28. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, et al.: Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin’s lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood 1997;89:3817–3825.

    PubMed  CAS  Google Scholar 

  29. Karras JG, Wang Z, Huo L, Howard RG, Frank DA, Rothstein TL: Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, selfrenewing B-l cells but only inducibly expressed in conventional B lymphocytes. J Exp Med. 1997;185:1035–1042.

    Article  PubMed  CAS  Google Scholar 

  30. Bellosillo B, Dalmau M, Colomer D, Gil J: Involvement of CED-3/ ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997;89:3378–3384.

    PubMed  CAS  Google Scholar 

  31. Sterry W, Mielke V: CD4+ cutaneous T cell lymphomas show the phenotype of helper/inducer T-cells (CD45RA-,CDw29+). J Invest Dermatol 1989;93:413–416.

    Article  PubMed  CAS  Google Scholar 

  32. Heald P, Yan S-L, Edelson R: Profound deficiency in normal circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 1994;130:198–203.

    Article  PubMed  CAS  Google Scholar 

  33. Bogen SA, Pelley D, Charif M, McCusker M, Koh H, Foss F, et al.: Immunophenotypic identification of Sezary’s cells in peripheral blood. Am J Clin Pathol 1996; 106:739–747.

    PubMed  CAS  Google Scholar 

  34. Edelson RL: Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 1980;2:89:106.

    PubMed  Google Scholar 

  35. Capocasale RJ, Lamb RJ, VonDerheid EC, Fox FE, Rook AH, Nowell PC, et al.: Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T-cells from Sézary patients. Proc Natl Acad Sci USA 1995;92:5501–5505.

    Article  PubMed  CAS  Google Scholar 

  36. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D:Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994;91:6002–6006.

    Article  PubMed  CAS  Google Scholar 

  37. Myeroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, et al.: A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545–5547.

    PubMed  CAS  Google Scholar 

  38. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al.: Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996;93:9148–9153.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 19104-6082, Philadelphia, PA

    Peter C. Nowell & Jonni S. Moore

Authors
  1. Peter C. Nowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonni S. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter C. Nowell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nowell, P.C., Moore, J.S. Aberrant responses of human lymphocytic neoplasms to cytokine regulation. Immunol Res 17, 171–177 (1998). https://doi.org/10.1007/BF02786442

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02786442

Key words

Search

Navigation